Javascript must be enabled to continue!
Perceptions, experiences and needs of patients with idiopathic pulmonary fibrosis
View through CrossRef
AbstractAimsTo understand the perceptions, needs and experiences of patients with Idiopathic Pulmonary Fibrosis.BackgroundIdiopathic pulmonary fibrosis is a progressive interstitial lung disease, with a mean life expectancy similar to some forms of cancer of 2–4 years from diagnosis. Unlike the cancer literature, which is rich with studies exploring the needs of their disease group, few publications exist on patient needs with this severe fibrotic lung disease.DesignA Qualitative study which took place between 2007–2012.MethodsSeventeen patients with a multidisciplinary team confirmed diagnosis of Idiopathic Pulmonary Fibrosis, with moderate to advanced disease severity and six of their informal carers were interviewed. An interview topic guide was developed by the researchers and service user group. The interviews were audio‐recorded, semi‐structured and took place at a regional respiratory and lung transplant centre in North West England. Interviews were transcribed verbatim and data analysed using Framework Analysis.FindingsThree main themes were identified: ‘Struggling to get a diagnosis’; ‘Loss of the life I previously had’; and ‘Living with Idiopathic Pulmonary Fibrosis’. Patients reported struggling to get a diagnosis and coping with a life‐limiting, rapidly progressive illness with no good treatment and few support structures.ConclusionsThere is an urgent need for a better understanding of the difficulties faced by people with Idiopathic Pulmonary Fibrosis and their carers. This can be used to develop better supportive care in the United Kingdom and ultimately improve the quality of life of these patients.
Title: Perceptions, experiences and needs of patients with idiopathic pulmonary fibrosis
Description:
AbstractAimsTo understand the perceptions, needs and experiences of patients with Idiopathic Pulmonary Fibrosis.
BackgroundIdiopathic pulmonary fibrosis is a progressive interstitial lung disease, with a mean life expectancy similar to some forms of cancer of 2–4 years from diagnosis.
Unlike the cancer literature, which is rich with studies exploring the needs of their disease group, few publications exist on patient needs with this severe fibrotic lung disease.
DesignA Qualitative study which took place between 2007–2012.
MethodsSeventeen patients with a multidisciplinary team confirmed diagnosis of Idiopathic Pulmonary Fibrosis, with moderate to advanced disease severity and six of their informal carers were interviewed.
An interview topic guide was developed by the researchers and service user group.
The interviews were audio‐recorded, semi‐structured and took place at a regional respiratory and lung transplant centre in North West England.
Interviews were transcribed verbatim and data analysed using Framework Analysis.
FindingsThree main themes were identified: ‘Struggling to get a diagnosis’; ‘Loss of the life I previously had’; and ‘Living with Idiopathic Pulmonary Fibrosis’.
Patients reported struggling to get a diagnosis and coping with a life‐limiting, rapidly progressive illness with no good treatment and few support structures.
ConclusionsThere is an urgent need for a better understanding of the difficulties faced by people with Idiopathic Pulmonary Fibrosis and their carers.
This can be used to develop better supportive care in the United Kingdom and ultimately improve the quality of life of these patients.
Related Results
Title: Idiopathic pulmonary fibrosis is a risk factor for cardiovascular disease; Potential role for systemic inflammation
Title: Idiopathic pulmonary fibrosis is a risk factor for cardiovascular disease; Potential role for systemic inflammation
Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, parenchymal disease, now considered as fatal disease of the lungs, characterized by pulm...
Allicin attenuates silica-induced pulmonary fibrosis via Serpinb2/NF-Kappa B pathway
Allicin attenuates silica-induced pulmonary fibrosis via Serpinb2/NF-Kappa B pathway
Abstract
Background
Silica-induced pulmonary fibrosis is a debilitating condition with limited therapeutic options. Allicin, a bioactive compound derived from garlic, has ...
Rapid pulmonary fibrosis induced by acute lung injury via a lipopolysaccharide three-hit regimen
Rapid pulmonary fibrosis induced by acute lung injury via a lipopolysaccharide three-hit regimen
Based on the common characteristic of severe acute respiratory syndrome (SARS) and highly pathogenic avian influenza and the mechanism of inflammation and fibrosis, it is speculate...
Assesment of factors for late diagnosis of idiopathic pulmonary arterial hypertension in real clinical practice
Assesment of factors for late diagnosis of idiopathic pulmonary arterial hypertension in real clinical practice
Idiopathic (primary) pulmonary arterial hypertension – a rare progressive disease that shortens life, usually diagnosed at a late stage. Therefore, it is critical to have a low thr...
Some Genetic Aspects of Idiopathic and Symptomatic Absence Seizures: Waking and Sleep EEGs in Siblings
Some Genetic Aspects of Idiopathic and Symptomatic Absence Seizures: Waking and Sleep EEGs in Siblings
Summary: Epileptic activity was recorded in the waking and sleep EEG of 62.5% of 80 siblings of 38 patients with absence seizures. Epileptic discharges were noted in waking only i...
VAP score as a novel non‐invasive liver fibrosis model in patients with chronic hepatitis C
VAP score as a novel non‐invasive liver fibrosis model in patients with chronic hepatitis C
AimAssessment of liver fibrosis in chronic hepatitis C (CHC) patients is necessary before antiviral treatment. This study aimed to evaluate the effectiveness of eight non‐invasive ...
The calpain inhibitor calpeptin prevents bleomycin-induced pulmonary fibrosis in mice
The calpain inhibitor calpeptin prevents bleomycin-induced pulmonary fibrosis in mice
SummaryPulmonary fibrosis is characterized by progressive worsening of pulmonary function leading to a high incidence of death. Currently, however, there has been little progress i...
Evaluating the effect of methotrexate on the rate of renal fibrosis by elastography and fibrosis-related gene expression
Evaluating the effect of methotrexate on the rate of renal fibrosis by elastography and fibrosis-related gene expression
Methotrexate is mainly used to treat diseases such as rheumatoid arthritis (RA), but its potential for nephrotoxicity has always been a significant concern on the use of this medic...

